Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma
Antineoplastic Combined Chemotherapy Protocols
Carcinoma, Renal Cell
The combination of everolimus and sunitinib is associated with significant acute and chronic toxicities and is only tolerated at attenuated doses. Responses were observed in nonclear cell and clear cell RCC.